SNORD113-6: SNORD113-6 is a C/D box small nucleolar RNA that is significantly downregulated in tumor tissues compared to normal liver tissue [PMC4169825]. Inhibition of SNORD113-6 in HUAFs leads to a trend towards a decreased ratio of the ITGB3-1 mRNA over the ITGB3-2 mRNA [PMC8976432]. This can be explained by the fact that under SNORD113-6 inhibition, there is a pre-mRNA processing preference for the mRNA variant that is marked for nonsense-mediated decay (NMD) [PMC8976432]. SNORD113-6 regulates cell-cell and cell-matrix interactions as well as cell migration, which are crucial for normal fibroblast function [PMC8976432]. Inhibition of SNORD113-6 also affects fibroblast barrier function and extracellular matrix contraction [PMC8976432]. The protein expression in HUAFs is decreased under SNORD113-6 inhibition [PMC8976432]. The binding sites of SNORD113-6 are not always located in the last exon of human genes [PMC8976432]. The inhibition of SNORD113-6 alters fibroblast function and integrin signaling pathway, which plays a crucial role in fibroblast cell-cell and cell-matrix interactions [PMC8976432]. Expression of SNORD113-6 is significantly upregulated under ischemic conditions [PMC9547152]. Inhibition of SNORD113-6 affects the phenotype transition from adventitial fibroblasts to myofibroblasts [PMC9547152]. C/D box snoRNAs associate with conserved ribonucleoproteins NHP2L1, NOP56, NOP58, and Fibrillarin (FBL) [PMC9547152].